An Active Surveillance to Monitor the Real World Safety in Indian Patients Prescribed Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
Phase of Trial: Phase IV
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 09 Aug 2017 Planned primary completion date changed from 30 Sep 2018 to 1 Dec 2018.
- 12 Apr 2017 Status changed from not yet recruiting to recruiting.
- 07 Mar 2017 Planned initiation date changed from 20 Feb 2017 to 1 Mar 2017.